Form 4: Kalaris Therapeutics Director Ferrara Napoleone Acquires 18,000 Stock Options
SEC Form 4 Filing
Director Ferrara Napoleone reports acquisition of 18,000 stock options in Kalaris Therapeutics, Inc.
Summary
- Ferrara Napoleone, a director of Kalaris Therapeutics, Inc., filed a Form 4 on April 11, 2025.
- The report details the acquisition of 18,000 stock options on April 10, 2025, at an exercise price of $7.31.
- These options vest in equal monthly installments over three years, from March 18, 2025, to March 18, 2028, contingent upon continuous service.
- Following the transaction, Napoleone directly owns 18,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Start date for monthly vesting of stock options. |
| 04/10/2025 | Date of transaction: Stock options granted. |
| 04/11/2025 | Date of Form 4 filing. |
| 03/18/2028 | End date for monthly vesting of stock options. |
| 04/09/2035 | Expiration date of the stock options. |
Keywords
Form 4, Kalaris Therapeutics, Stock Options, Director, Ferrara Napoleone, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.